Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical application of gonadotropin-releasing hormone analogs in children and adolescents

  • Kim, Ho-Seong (Department of Pediatrics, College of Medicine, Yonsei University)
  • Received : 2010.02.18
  • Accepted : 2010.02.22
  • Published : 2010.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Although the increasing incidence of central precocious puberty (CPP) in Korea has recently raised public concerns about health and growth problems, there are many areas of uncertainty regarding the pathogenesis, diagnosis, and management of CPP. In this paper, we review the definition of precocity, the assessment of CPP, and the hormonal abnormalities that support the diagnosis. In addition, we review the practical guidelines regarding the clinical use of gonadotropin-releasing hormone analogs in children with CPP. Indications for treatment, determination of dosage, monitoring during treatment, and discontinuation of therapy are discussed.

Keywords

References

  1. Grumbach MM, Styne DM. Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology. 10th ed Philadelphia: Saunders, 2003;1115-67
  2. Rosenfield RL, Cooke DW, Radovick S. Puberty and its disorders in the female. In: Sperling MA, editor. Pediatric endocrinology 3rd ed. Philadelphia: Saunders, 2008;530-609
  3. Kim TH, Coe HJ, Kim S, Lee SW, Chae H-W, Kim YS, et al. Clinical and endocrinologic characteristics of children referred for precocious puberty. J Korean Soc Pediatr Endocrinol 2007;12:119-26
  4. Hur K, Park MJ. Five year national trend of precocious puberty in Korean children, 2004-2008. Program and Abstracts, the 58th Annual Fall Meeting of the Korean Pediatric Society; 2009 Oct 23-24; Seoul. Seoul: The Korean Pediatric Society 2009:179
  5. Partsch C-J, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002;56:129-48 https://doi.org/10.1046/j.0300-0664.2001.01490.x
  6. Schwarz HP, Tschaeppeler H, Zuppinger K. Unsustained central sexual precocity in four girls. Am J Med Sci 1990;299:260-4
  7. Kolmer M, Schulz U, Herkner K, Frisch H, Waldhauser F. Undulating course of precocious puberty. Padiatr Padol 1991;26:271-4
  8. Carel J-C, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-62 https://doi.org/10.1542/peds.2008-1783
  9. Rosense EA, Lara BH, Reis JD, Ferriera BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007;92:1424-9 https://doi.org/10.1210/jc.2006-1569
  10. Neely EK, Hintz RL, Wilson DM, Lee PA, Gaultier T, Argente J, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995;127:40-6 https://doi.org/10.1016/S0022-3476(95)70254-7
  11. Trivin C, Couto-Silva AC, Sainte-Rose C, Chemalitilly W, Kalifa C, Doz F, et al. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol (Oxf) 2006;65:239-45 https://doi.org/10.1111/j.1365-2265.2006.02582.x
  12. Chalumeau M, Hadjiathanasiou CG, Ng SM, Cassio A, Mul D, Cisternino M, et al. Selecting girls with precocious puberty for brain imaging: validation of European evidence-based diagnosis rule. J Pediatr 2003;143:445-50 https://doi.org/10.1067/S0022-3476(03)00328-7
  13. Cisternino M, Arrigo T, Pasquino AM, Tinelli C, Antoniazzi F, Beduschi L, et al. Etiology and age incidence of precocious puberty in girls; a multicentric study. J Pediatr Endocrinol Metab 2000;13 Supple 1:S695-701
  14. de Vries L, Horev G, Schwartz M, Phillip M. Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol 2006;154:891-8 https://doi.org/10.1530/eje.1.02151
  15. Haber HP, Wollmann HA, Ranke MB. Pelvic ultrasonography: early differentiation between isolated premature thelarche and central precocious puberty. Eur J Pediatr 1995;154:182-6 https://doi.org/10.1007/BF01954267
  16. Comite F, Culter GB Jr, Rivier J, Vale WW, Loriaux DL, Crowley WF Jr. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormonereleasing hormone. N Engl J Med 1981;305:1546-50 https://doi.org/10.1056/NEJM198112243052602
  17. Laron Z, Kauli R, Zeev ZB, Comaru-Schally AM, Schally AV. D-TRP5-analogue of luteinizing releasing hormone in combination with cyproterone acetate to treat precocious puberty. Lancet 1981;2:955-6
  18. Carel JC, Lahlou N, Jaramillo O, Mantauban V, Teinturier C, Colle M, et al. Treatment of central precocious puberty by subcutaneous injections of Leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111-6 https://doi.org/10.1210/jc.2001-020243
  19. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparison of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862-7 https://doi.org/10.1210/jc.2005-1500
  20. Tanaka T, Hibi I, Kato K, Saito S, Shimizu N, Suwa S, et al. A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolode acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group. Endocrinol Jpn 1991;38:369-76 https://doi.org/10.1507/endocrj1954.38.369
  21. Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs 2007;16:1851-63 https://doi.org/10.1517/13543784.16.11.1851
  22. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303 https://doi.org/10.1136/adc.44.235.291
  23. Bar A, Linder B, Sobel EH, Saenger P, DiMartino-Nardi J. Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height. J Pediatr 1995;126:955-8 https://doi.org/10.1016/S0022-3476(95)70221-0
  24. Klein KO, Baron J, Barnes KM, Pescovitz OH, Cutler GB Jr. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 1998;83:2387-9 https://doi.org/10.1210/jc.83.7.2387
  25. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hormone determination 2 hours after depot leu prolide is useful for therapy monitoring of gonadotropindependent precocious puberty in girls. J Clin Endocrinol Metab 2004;89:4338-4 https://doi.org/10.1210/jc.2003-031537
  26. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow-release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999;84:1973-8 https://doi.org/10.1210/jc.84.6.1973
  27. Ohyama K, Tanaka T, Tachibana K, Niimi H, Fujieda K, Matsuo N, et al. Timing for discontinuation of treatment with a long-acting gonadotropin-releasing hormone analog in girls with central precocious puberty. TAP-144SR CPP Study Group. Endocr J 1998;45:351-6 https://doi.org/10.1507/endocrj.45.351
  28. Arrigo T, Cisternino M, Galluzzi F, Bertolloni S, Pasquino AM, Antoniazzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140-4 https://doi.org/10.1530/eje.0.1410140
  29. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480-8 https://doi.org/10.1210/jc.84.12.4480
  30. Bertollini S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropinreleasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998;157:363-7 https://doi.org/10.1007/s004310050831
  31. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, DiNardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190-5
  32. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-6 https://doi.org/10.1210/jc.86.10.4711
  33. Pasquino AM, Pucarelli I, Segni M, Matrnola M, Cerroni F, Cerrone F. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab 1999;84:449-52 https://doi.org/10.1210/jc.84.2.449
  34. Heger S, Muller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254-255:217-20 https://doi.org/10.1016/j.mce.2006.04.012
  35. Dorn LD. Psychological and social problems in children with premature adrenarche and precocious puberty. In: Pescovitz OH, Walvoord EC, editors. When puberty is precocious: scientific and clinical aspects. 12th edition. Totowa: Humana Press, 2007:309-327
  36. Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002;87:2090-4 https://doi.org/10.1210/jc.87.5.2090
  37. Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs. J Pediatr Endocrinol Metab 2004;17:759-66 https://doi.org/10.1515/JPEM.2004.17.5.759
  38. Reiter EO, Lindberg A, Ranke MB, Price DA, Albertsson-Wikland K, Cowell CT, et al. The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency. Horm Res 2003;60 Suppl 1:S68-73
  39. Saggese G, Federico G, Barsanti S, Fiore L. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. J Clin Endocrinol Metab 2001;86:1900-4 https://doi.org/10.1210/jc.86.5.1900
  40. Carel JC. Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol Cell Endocrinol 2006;254-255:226-33 https://doi.org/10.1016/j.mce.2006.04.034